编者按：肺癌是全球发病率和死亡率最高的癌症之一。近20年来，随着 ...

Experts emphasize recording smoking status in cancer trials to improve treatment efficacy, survival, and outcomes, urging ...

Zeng and colleagues noted that while the use of a tyrosine kinase inhibitor plus an immune checkpoint inhibitor has become ...

Since 2014, research has increasingly shown that continued tobacco use negatively impacts patients receiving surgery, ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 1/1b study titled ‘A ...

埃万妥单抗联合兰泽替尼的国内获批，标志着EGFR敏感突变晚期NSCLC一线治疗正式迈入“双抗时代”。这一创新方案通过协同阻断关键信号通路并激活免疫机制，实现了患者生存期的显著提升，中位OS预计超4年，为长生存目标带来突破性进展。同时，该方案展现出优异的颅内疾病控制能力，并有效优化耐药谱，显著延缓耐药发生。尤其重要的是，它为传统治疗困境下的高危患者群体（如脑转移、肝转移及伴随特定基因异常者）提供了极 ...

前言随着精准诊疗理念和技术的不断发展以及患者对生存延长的迫切需求，表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）已成为早中期完全切除的EGFR突变非小细胞肺癌（NSCLC）患者辅助治疗的标准治疗方案。在临床实践不断推进的过程中，如何确定EGFR ...

Patient enrollment for our ongoing Phase-3 clinical trial of SGT-610 for Gorlin Syndrome has been completed; top-line results are expect ...

Johnson & Johnson launches The 3rd Opinion in Asia Pacific: a new term to elevate the patient voice in the lung cancer treatment journey ...

EGFR抑制剂厄洛替尼 (Erlotinib)处理的小鼠中，Art未能进一步改善肥胖和肝脏功能指标。 细胞实验显示，在EGFR沉默或抑制的HepG2细胞中，Art对脂质合成相关基因 (fasn、acc、scd1)的抑制作用消失。